The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| AURA | -44.53% | N/A | N/A | -63% |
| S&P | +12.57% | +87.93% | +13.44% | +46% |
Aura Biosciences, Inc. is a clinical-stage oncology company, which engages in developing a novel technology platform based on virus-like drug conjugates (VDCs) to target and destroy cancer cells selectively while activating the immune system to create long lasting anti-tumor immunity. The firm's product candidate belzupacap sarotalocan (AU-011) is in Phase 2 development for the first line treatment of choroidal melanoma, a vision and life-threatening form of eye cancer where standard of care radioactive treatments leave patients with major vision loss and severe comorbidities. The was founded by Elisabet de los Pinos in 2007 and is headquartered in Boston, MA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.30M | 4.2% |
| Market Cap | $383.90M | -13.1% |
| Market Cap / Employee | $3.62M | 0.0% |
| Employees | 106 | 19.1% |
| Net Income | -$26.13M | -24.2% |
| EBITDA | -$27.61M | -20.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $47.55M | 87.2% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $14.53M | -8.9% |
| Short Term Debt | $3.22M | 3.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -53.86% | -10.6% |
| Return On Invested Capital | -49.73% | 5.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$20.19M | -29.3% |
| Operating Free Cash Flow | -$20.14M | -31.9% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.34 | 1.93 | 2.46 | 2.20 | -4.80% |
| Price to Tangible Book Value | 2.34 | 1.93 | 2.46 | 2.20 | -4.80% |
| Enterprise Value to EBITDA | -10.44 | -9.66 | -6.51 | -7.39 | -17.87% |
| Return on Equity | -46.0% | -56.2% | -55.4% | -64.3% | 26.03% |
| Total Debt | $18.77M | $18.44M | $18.11M | $17.75M | -6.97% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
